FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 702 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Holidays, Traditions and Grief December 21, 2020 Change Your Thoughts, Change Your World March 17, 2021 FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma August 22, 2025 The Largest Randomised Study to Date Points to Low Ipsilateral Breast... June 22, 2023 Load more HOT NEWS Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... Food for Thought: A Fresh Perspective on Nutrition FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions
